Ocugen price target raised to $22 from $15 at Lucid Capital
Lucid Capital analyst Elemer Piros raised the firm’s price target on Ocugen (OCGN) to $22 from $15 and keeps a Buy rating on the shares. The company announced positive preliminary Phase 2 data for OCU410 in geographic atrophy, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Read More on OCGN:
- Ocugen’s Gene Therapy Pipeline Dominates Earnings Call
- Ocugen: Late-Stage Retinal Pipeline and 2027–2028 Approval Catalysts Underpin Buy-Rated Risk‑Reward
- Ocugen’s Growing Pains: High Execution and Compliance Risks Threaten Shareholder Value
- Ocugen Seeks Court Validation of Charter Amendment Dispute
- Ocugen reports Q4 EPS (6c), consensus (6c)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Rare Earths Americas doubles mineralized zone at Homer project in Brazil
Wall Street Trading Booms on Crypto Exchanges. Which Tokens Benefit?
CEREBRAS SYSTEMS INC <CBRS.O>: MIZUHO CUTS TARGET PRICE TO $240.00 FROM $300.00
Allarity Therapeutics Sees FY Loss/Shr 73c-Loss 76c >ALLR
Crypto prices
More
